Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNFT NASDAQ:IOVA NASDAQ:NRIX NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNFTGENFIT$4.29-0.3%$4.07$2.55▼$6.03$215.01M1.187,517 shs1,609 shsIOVAIovance Biotherapeutics$2.25+2.7%$2.27$1.64▼$12.51$792.46M0.8311.50 million shs9.27 million shsNRIXNurix Therapeutics$11.09+6.6%$9.49$8.18▼$29.56$799.59M2.331.50 million shs2.46 million shsRZLTRezolute$9.19+1.9%$8.14$2.21▼$10.04$819.27M0.041.66 million shs868,239 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNFTGENFIT-0.23%+3.49%+18.11%+11.10%-24.47%IOVAIovance Biotherapeutics+1.86%-2.23%+5.80%-30.03%-77.70%NRIXNurix Therapeutics-2.16%+3.69%+26.21%-9.72%-58.03%RZLTRezolute-8.24%+1.69%+5.87%+43.17%+68.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNFTGENFIT$4.29-0.3%$4.07$2.55▼$6.03$215.01M1.187,517 shs1,609 shsIOVAIovance Biotherapeutics$2.25+2.7%$2.27$1.64▼$12.51$792.46M0.8311.50 million shs9.27 million shsNRIXNurix Therapeutics$11.09+6.6%$9.49$8.18▼$29.56$799.59M2.331.50 million shs2.46 million shsRZLTRezolute$9.19+1.9%$8.14$2.21▼$10.04$819.27M0.041.66 million shs868,239 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNFTGENFIT-0.23%+3.49%+18.11%+11.10%-24.47%IOVAIovance Biotherapeutics+1.86%-2.23%+5.80%-30.03%-77.70%NRIXNurix Therapeutics-2.16%+3.69%+26.21%-9.72%-58.03%RZLTRezolute-8.24%+1.69%+5.87%+43.17%+68.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNFTGENFIT 2.00Hold$7.0063.36% UpsideIOVAIovance Biotherapeutics 2.27Hold$11.90428.89% UpsideNRIXNurix Therapeutics 2.83Moderate Buy$27.07144.06% UpsideRZLTRezolute 2.88Moderate Buy$14.5057.78% UpsideCurrent Analyst Ratings BreakdownLatest GNFT, IOVA, NRIX, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/23/2025NRIXNurix TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$22.00 ➝ $21.0010/23/2025NRIXNurix TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$35.00 ➝ $27.0010/22/2025NRIXNurix TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$29.0010/21/2025NRIXNurix TherapeuticsMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$24.0010/20/2025NRIXNurix TherapeuticsMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/20/2025NRIXNurix TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.0010/20/2025NRIXNurix TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$33.0010/14/2025NRIXNurix TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$34.00 ➝ $33.0010/14/2025GNFTGENFITWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/14/2025NRIXNurix TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$16.00 ➝ $15.0010/13/2025NRIXNurix TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$22.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNFTGENFIT$76.77M2.79$0.07 per share61.48$1.50 per share2.86IOVAIovance Biotherapeutics$164.07M4.96N/AN/A$2.33 per share0.97NRIXNurix Therapeutics$54.55M15.63N/AN/A$4.84 per share2.29RZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/AN/AIOVAIovance Biotherapeutics-$372.18M-$1.23N/AN/AN/A-161.44%-52.87%-41.31%11/6/2025 (Estimated)NRIXNurix Therapeutics-$193.57M-$2.97N/AN/AN/A-292.50%-53.57%-40.82%N/ARZLTRezolute-$74.41M-$0.97N/AN/AN/AN/A-65.03%-58.86%11/6/2025 (Estimated)Latest GNFT, IOVA, NRIX, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025IOVAIovance Biotherapeutics-$0.28N/AN/AN/A$76.20 millionN/A11/6/2025Q1 2026RZLTRezolute-$0.27N/AN/AN/AN/AN/A10/9/2025Q3 2025NRIXNurix Therapeutics-$0.84-$1.03-$0.19-$1.03$16.06 million$7.89 million9/17/2025Q4 2025RZLTRezolute-$0.23-$0.26-$0.03-$0.26N/AN/A8/7/2025Q2 2025IOVAIovance Biotherapeutics-$0.29-$0.33-$0.04-$0.33$67.14 million$59.95 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNFTGENFITN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNFTGENFIT0.093.743.74IOVAIovance BiotherapeuticsN/A3.272.89NRIXNurix TherapeuticsN/A5.355.35RZLTRezoluteN/A14.3714.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNFTGENFIT2.24%IOVAIovance Biotherapeutics77.03%NRIXNurix TherapeuticsN/ARZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipGNFTGENFIT4.20%IOVAIovance Biotherapeutics10.30%NRIXNurix Therapeutics7.40%RZLTRezolute14.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableIOVAIovance Biotherapeutics500361.85 million324.58 millionOptionableNRIXNurix Therapeutics30076.88 million71.19 millionOptionableRZLTRezolute4090.83 million77.40 millionOptionableGNFT, IOVA, NRIX, and RZLT HeadlinesRecent News About These CompaniesRezolute (NASDAQ:RZLT) Trading Down 6.4% - Time to Sell?October 24 at 1:18 PM | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 23 at 3:49 AM | americanbankingnews.comRezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Moderate Buy" from BrokeragesOctober 23 at 3:47 AM | marketbeat.comRezolute (NASDAQ:RZLT) Hits New 1-Year High - Time to Buy?October 22 at 12:08 PM | marketbeat.comRezolute to Participate in Upcoming Investor ConferencesOctober 15, 2025 | globenewswire.comRezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 9, 2025 | globenewswire.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Rezolute (NASDAQ:RZLT)October 9, 2025 | marketbeat.comRezolute, Inc. ($RZLT) CEO 2025 Pay RevealedOctober 7, 2025 | quiverquant.comQRezolute (NASDAQ:RZLT) Sets New 1-Year High - Still a Buy?October 2, 2025 | marketbeat.comCantor Fitzgerald Weighs in on Rezolute FY2026 EarningsOctober 1, 2025 | marketbeat.comWe're Not Very Worried About Rezolute's (NASDAQ:RZLT) Cash Burn RateSeptember 29, 2025 | finance.yahoo.comRezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of "Buy" from AnalystsSeptember 28, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Stock Price Up 7.6% - Still a Buy?September 26, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Reaches New 52-Week High - Still a Buy?September 25, 2025 | marketbeat.comGoldman Sachs Group Inc. Invests $685,000 in Rezolute, Inc. $RZLTSeptember 25, 2025 | marketbeat.comRezolute price target raised to $20 from $15 at MaximSeptember 19, 2025 | msn.comRezolute, Inc.: Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 18, 2025 | finanznachrichten.deRezolute, Inc. Reports Fiscal 2025 Financial ResultsSeptember 17, 2025 | tipranks.comRezolute reports Q4 EPS (26c), consensus (23c)September 17, 2025 | msn.comRezolute, Inc. Reports Q4 and Full Year Fiscal 2025 Financial Results and Updates on Ersodetug Development ProgressSeptember 17, 2025 | quiverquant.comQRezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 17, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNFT, IOVA, NRIX, and RZLT Company DescriptionsGENFIT NASDAQ:GNFT$4.28 -0.02 (-0.35%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Iovance Biotherapeutics NASDAQ:IOVA$2.25 +0.06 (+2.74%) Closing price 04:00 PM EasternExtended Trading$2.26 +0.00 (+0.22%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Nurix Therapeutics NASDAQ:NRIX$11.09 +0.69 (+6.63%) Closing price 04:00 PM EasternExtended Trading$10.94 -0.15 (-1.34%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Rezolute NASDAQ:RZLT$9.19 +0.17 (+1.88%) Closing price 04:00 PM EasternExtended Trading$9.10 -0.09 (-1.03%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
